Navigation Links
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Date:2/27/2012

rces to better penetrate its growing hospital network. Sales and marketing expenses accounted for 17.9% of revenues in the third quarter of fiscal 2012.
  • General and Administrative Expenses.  General and administrative expenses remained roughly in line with previous quarters at RMB22.7 million ($3.6 million), compared to RMB20.2 million in the prior year period. General and administrative expenses as a percentage of revenues represented approximately 24.0%.
  • NET INCOME ATTRIBUTABLE TO SHAREHOLDERS.  Net income attributable to shareholders for the third quarter of fiscal 2012 increased by 52.5% to RMB39.5 million ($6.3 million) from RMB25.9 million in the prior year period, mainly due to the discrete tax benefit of RMB7.8 million ($1.2 million) from the preferential tax treatment for our Beijing subsidiary, and a RMB3.5 million ($0.6 million) exchange rate gain during the quarter. Under the preferential tax treatment, the Beijing subsidiary is qualified for a reduced tax rate of 15% through December 31, 2013, compared to 25% in previous quarters. Net margin for the third quarter of fiscal 2012 rose to 41.6% from 28.6% in the prior year period. Basic and diluted earnings per share for the third quarter of fiscal 2012 were RMB0.54 ($0.09).

    LIQUIDITY.  As of December 31, 2011, the Company had cash and cash equivalents of RMB716.7 million ($113.9 million) compared to RMB611.4 million as of March 31, 2011. The Company had bank loan borrowings of RMB45.0 million ($7.2 million) as of December 31, 2011.

    First Nine Months Fiscal 2012 Financial ResultsFor first nine months of fiscal 2012, total revenues increased 14.6% to RMB280.7 million ($44.6 million) from RMB244.9 million in the prior year period. The increase was largely attributable to the processing fee increase effective from April 2011 and the expansion of the Company's accumulated subscriber base to 225,418 subscribers. During t
    '/>"/>

    SOURCE China Cord Blood Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
    2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
    3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
    4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
    5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
    6. China Medicine Announces Strong Second Quarter 2008 Results
    7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
    8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
    9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
    10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
    11. China Biologic Products Reports Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
    (Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
    (Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
    (Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
    Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
    ... New System to Streamline Process, Drive Value from ... Software Inc., a leading,provider of web-based employee performance ... been selected by Quiznos to provide a system,for ... is a,national chain with over 5000 franchise restaurants, ...
    ... Alimera Sciences,and pSivida Ltd (Nasdaq: PSDV ... have amended their license and collaboration agreement relating ... for,diabetic macular edema (DME), and other Medidur products. ... of Medidur FA from 50 to 80,percent in ...
    ... Million Distribution Contract from Anhui ... Huayuan Pharmaceutical Co., ... Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and,supplier ... today announced that the Company has been granted SFDA,approval ...
    Cached Biology Technology:Quiznos Selects Halogen for Fresh Approach to Talent Management 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3
    (Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
    (Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
    (Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
    Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
    ... Taking aim at a leading cause of ... at the Massachusetts Biologic Laboratories (MBL) of the University of ... that neutralizes the Hepatitis C virus (HCV). The new ... infection by the virus in a pre-clinical animal model of ...
    ... details of a membership agreement with BioMed Central to ... researchers. Pfizer,s BioMed Central membership arrangement means that ... researcher employed or funded by Pfizer when they submit ... peer-reviewed open access journals. By funding open access publication ...
    ... of Guam Associate Professor Laurie Raymundo is senior editor ... and management of coral diseases, " Coral Disease Handbook: ... summarizes the most recently developed methods for studying the ... the book is a set of identification cards for ...
    Cached Biology News:Novel antibody prevents infection by hepatitis C virus 2Novel antibody prevents infection by hepatitis C virus 3
    BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
    Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
    ... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
    ...
    Biology Products: